MBOAT2 and central nervous system cancer: In addition, using the GEPIA database, we found that the MBOAT2 level was dramatically higher in pancreatic adenocarcinoma, breast invasive carcinoma, prostate adenocarcinoma, cholangiocarcinoma, pheochromocytoma, paraganglioma, and brain lower-grade glioma (Figure 2(a)).